- Home
- SPFI vs STOK Comparison
SPFI vs STOK Comparison
Compare SPFI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- STOK
- Stock Information
- Founded
- SPFI 1941
- STOK 2014
- Country
- SPFI United States
- STOK United States
- Employees
- SPFI N/A
- STOK N/A
- Industry
- SPFI Major Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- STOK Health Care
- Exchange
- SPFI Nasdaq
- STOK Nasdaq
- Market Cap
- SPFI 624.7M
- STOK 721.4M
- IPO Year
- SPFI 2019
- STOK 2019
- Fundamental
- Price
- SPFI $39.46
- STOK $11.43
- Analyst Decision
- SPFI Buy
- STOK Strong Buy
- Analyst Count
- SPFI 2
- STOK 7
- Target Price
- SPFI $33.50
- STOK $21.40
- AVG Volume (30 Days)
- SPFI 39.8K
- STOK 470.9K
- Earning Date
- SPFI 10-23-2024
- STOK 11-05-2024
- Dividend Yield
- SPFI 1.52%
- STOK N/A
- EPS Growth
- SPFI N/A
- STOK N/A
- EPS
- SPFI 2.56
- STOK N/A
- Revenue
- SPFI $183,911,000.00
- STOK $16,742,999.00
- Revenue This Year
- SPFI N/A
- STOK $91.67
- Revenue Next Year
- SPFI $6.18
- STOK $5.45
- P/E Ratio
- SPFI $15.40
- STOK N/A
- Revenue Growth
- SPFI N/A
- STOK 81.08
- 52 Week Low
- SPFI $24.05
- STOK $3.77
- 52 Week High
- SPFI $40.91
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- SPFI 63.68
- STOK 36.03
- Support Level
- SPFI $36.90
- STOK $11.08
- Resistance Level
- SPFI $40.91
- STOK $11.73
- Average True Range (ATR)
- SPFI 1.22
- STOK 0.73
- MACD
- SPFI -0.03
- STOK -0.23
- Stochastic Oscillator
- SPFI 78.95
- STOK 9.62
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has two reportable segments: banking and insurance.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.